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Abstract
Background: Depression during pregnancy is a common and high impact disease. Generally, 5–10 % of pregnant
women suffer from depression. Children who have been exposed to maternal depression during pregnancy have a
higher risk of adverse birth outcomes and more often show cognitive, emotional and behavioural problems. Therefore,
early detection and treatment of antepartum depression is necessary. Both psychotherapy and antidepressant
medication, first choice treatments in a non-pregnant population, have limitations in treating depression during
pregnancy. Therefore, it is urgent and relevant to investigate alternative treatments for antepartum depression.
Bright light therapy (BLT) is a promising treatment for pregnant women with depressive disorder, for it combines
direct availability, sufficient efficacy, low costs and high safety, taking the safety for the unborn child into account as well.
Methods: In this study, 150 pregnant women (12–18 weeks pregnant) with a DSM-V diagnosis of depressive
disorder will be randomly allocated in a 1:1 ratio to one of the two treatment arms: treatment with BLT (9.000 lux)
or treatment with dim red light therapy (100 lux). Both groups will be treated for 6 weeks at home on a daily basis
for 30 min, within 30 min of habitual wake-up time. Follow-up will take place after 6 weeks of therapy, 3 and 10 weeks
after end of therapy, at birth and 2, 6 and 18 months postpartum. Primary outcome will be the average change in
depressive symptoms between the two groups, as measured by the Structured Interview Guide for the Hamilton
Depression Scale – Seasonal Affective Disorder version and the Edinburg Postnatal Depression Scale. Changes in
rating scale scores of these questionnaires over time will be analysed using generalized linear mixed models.
Secondary outcomes will be the changes in maternal cortisol and melatonin levels, in maternal sleep quality and
gestational age, birth weight, infant behaviour, infant cortisol exposure and infant cortisol stress response.
Discussion: If BLT reduces depressive symptoms in pregnant women, it will provide a safe, cheap, non-pharmacological
and efficacious alternative treatment for psychotherapy and antidepressant medication in treating antepartum
depression, without any expected adverse reactions for the unborn child.
Trial registration: Netherlands Trial Register NTR5476. Registered 5 November 2015.
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Background
Depression during pregnancy is a common and high
impact disease. Approximately 5–10 % of pregnant
women suffers from depression [1], which has been
confirmed by a study in Rotterdam, the second largest
city in the Netherlands [2]. Children who are exposed
to maternal depression during pregnancy have a higher
risk of adverse birth outcomes, such as low birth
weight, and more often show cognitive, emotional and
behavioural problems [3–6]. The perinatal period is a
critical period, in which epigenetic programming deter-
mines not only the perinatal health, but also that of fol-
lowing generations [7]. Therefore, early detection and
prompt treatment of depression during pregnancy can
benefit both mother and child.
In non-pregnant women, guidelines propose psycho-
therapy, antidepressant medication or a combination of
both as treatment for depression. However, clinical
practice shows limited relevance of these guidelines
during pregnancy, as the direct availability of psycho-
therapists is poor, postponing treatment for several
months or more. In pregnancy, the window of oppor-
tunity is small and from the perspective of the child
postponement is in fact non-treatment. Other limita-
tions of psychotherapy are its dependence on good lan-
guage skills, absence of problems that limit access to
therapy and a strong motivation to reflect on ones
emotions, cognition and behaviour. These factors limit
the applicability of psychotherapy in a majority of preg-
nant women with depression, who share a socioeco-
nomic deprived background and often have coexisting
problems interfering with compliance [8]. Therefore,
women with depression during pregnancy may be
treated with antidepressants. In North America, use of
antidepressants during pregnancy is reported by 5–13 %
of pregnant women [9, 10]. In the Netherlands, 2–3 % of
pregnant women use antidepressant medication [11, 12].
However, the safety of these medications during preg-
nancy is controversial [13, 14].
Therefore, investigating non-pharmacological approaches
to treating depression during pregnancy is urgent and
relevant, for both mother and child. Bright light therapy
(BLT) is a promising treatment for pregnant women
with depression based on several theoretical and clinical
considerations, which will be discussed below.
BLT and depression
BLT is the first choice treatment for seasonal affective
disorder (SAD) [15], a condition of reoccurring depres-
sions during fall and winter, with remissions in spring
and summer [16].
The effects of BLT have not only been consistently
shown on SAD [16–19], but also on other diseases,
such as non-seasonal depression [17], adult attention-
deficit/hyperactivity disorder [20] and bulimia nervosa
[21, 22]. The effects of BLT on non-seasonal depression
have been shown in various populations, like elderly
residents of group care facilities and patients with
Alzheimer’s disease [23–25].
BLT has been shown to synchronize the biological
clock with the environmental day-night rhythm and to
shift the circadian rhythm [15, 16]. Evidence suggests
that this mediates the effects of BLT on depression,
which has been indirectly supported by enhanced sleep
and rhythms of melatonin and cortisol [23].
Hypothalamus-pituitary-adrenal axis
The hypothalamus-pituitary-adrenal gland (HPA) axis is
involved in the synchronization of the biological clock
by BLT. This axis regulates the secretion of cortisol in
response to stress [26]. HPA-axis activity is controlled
by the corticotropin-releasing factor (CRF) secreted by
parvocellular neurosecretory cells in the paraventricular
nucleus (PVN) of the hypothalamus, which activates the
secretion of adrenocorticotrophic hormone (ACTH)
from the anterior pituitary, which in turn stimulates the
production and release of cortisol from the adrenal cortex
[26, 27]. CRF and ACTH are both inhibited by cortisol
through the glucocorticoid receptor (GR) [26, 27]. Figure 1
shows a schematic overview of this feedback loop.
Fig. 1 Schematic diagram of the hypothalamus-pituitary-adrenal
gland (HPA) axis. Shown are the different structures and hormones
involved in the HPA-axis. CRF, produced and released by the
hypothalamus, stimulates the anterior pituitary to produce and
release ACTH, which in turn stimulates the production and
release of cortisol by the adrenal cortex. Cortisol inhibits both the
hypothalamus and pituitary through the GR. PVN = paraventricular
nucleus; GR = glucocorticoid receptor; CRF = adrenocorticotrophic
hormone releasing factor; ACTH = adrenocorticotrophic hormone;
+ = stimulating; − = inhibiting
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The cause of depression is largely unknown. However,
the HPA-axis is thought to play a crucial role in the
pathophysiology – as cause or consequence, since
hyperactivity of this axis is associated with depression.
More specifically, depression is thought to be related to
reduced inhibition by cortisol, due to impaired GR
function [27]. This is supported by a post-mortem
study among depressed patients, which showed hyper-
activity of CRF neurons of the hypothalamic PVN [28].
Second, increased basal cortisol levels are commonly
found in patients with depression [27].
Suprachiasmatic nucleus
The suprachiasmatic nucleus (SCN), known as the
‘biological clock’, controls the HPA-axis: decreased in-
hibitory control of the SCN on the HPA-axis has been
shown to be associated with HPA-axis hyperactivity
[29]. The SCN is located in the hypothalamus on top
of the optic chiasm and is the central pacemaker of all
physiological and behavioural rhythms [15, 30]. Light
is the most powerful environmental signal that syn-
chronizes the SCN with the environmental day-night
rhythm (also known as ‘zeitgeber’). Environmental
light versus darkness is signalled to the SCN by
melanopsin-containing retinal ganglion cells through
the retino-hypothalamic tract in the optic nerve (Fig. 2)
[15, 31]. The SCN is able to maintain circadian
rhythms, even in the absence of zeitgebers [15, 30].
This central control function of circadian rhythms is
lost when the SCN is damaged or obliterated. Mice
studies have shown that ablation of the SCN results in
arrhythmicity [32, 33]. A case report of a patient with
hypothalamic damage demonstrated disturbances in
the sleep-wake cycle, body temperature and cognitive
and behavioural functioning [34].
Melatonin
Melatonin is, next to cortisol, influenced by light. Mela-
tonin is produced and secreted by the pineal gland and,
like other circadian rhythms, its rhythm is controlled by
the SCN (Fig. 2) [35, 36]. Typically, melatonin levels rise
in the evening, peak at early morning hours and drop to
baseline at awakening [26]. Light inhibits the production
of melatonin [26].
Different studies showed a change in melatonin se-
cretion in psychiatric diseases, such as a reduction of
melatonin secretion in depression [35, 37]. Earlier, BLT
in the morning has been shown to normalize saliva
melatonin evening levels in elderly patients with a de-
pressive disorder [23].
Melatonin concentrations increase during the course
of pregnancy [36]. However, a study showed that noc-
turnal melatonin levels were lower in depressed preg-
nant women, compared to healthy controls [38]. In this
study, we want to explore the effects of BLT on evening
and morning melatonin levels.
BLT and depression during pregnancy
The SCN generates the circadian rhythms in physiology
and behaviour, including reproductive hormones. Preg-
nant women typically show disturbed, desynchronised
circadian rhythms, resulting in disturbed sleep patterns,
which puts them at risk for depression [39]. Moreover,
disturbed sleep and decreased physical condition put
pregnant women at risk for decreased activity and less
exposure to daylight [40], which might further enhance
their risk for depression.
Two small (n = 10 and n = 27) randomized controlled
trials among pregnant women with non-seasonal de-
pression showed significant improvement of depression
among women exposed to BLT compared to placebo
Fig. 2 Sagittal view of the brain. This figure shows a sagittal view of the suprachiasmatic nucleus, the optic chiasm, the optic nerve, the
hypothalamus, the pituitary and the pineal gland
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[41, 42]. Treatment effect in terms of mean improve-
ment of depressive symptoms was comparable with the
effects of antidepressant medication (effect size around
0.45), making it a competitive treatment for antepartum
depression, but without the possible adverse effects of
medication to the unborn child. Although these studies
provide evidence for the effectiveness of BLT for de-
pression during pregnancy, their sample size is small.
While in previous studies among elderly patients corti-
sol and melatonin rhythms normalized after BLT treat-
ment [23], the question is whether improvement of
depressive symptoms after BLT in pregnant women is
also mediated through improved endocrine functioning
or whether these symptoms are primarily determined by
the physiology of pregnancy itself. Therefore, we will
also examine the circadian rhythms and hormone levels
of the pregnant women, to study whether BLT also ef-
fects endocrine functioning during pregnancy.
From previous research, we know that maternal de-
pression during pregnancy negatively influences intra-
uterine and postnatal child development [3–6, 43–47].
How intra-uterine child development is influenced by
maternal depression has yet to be determined. Possible
mechanisms are maternal cortisol crossing the placenta,
placental secretion of CRH – which has a positive feed-
back loop with maternal and foetal cortisol – and re-
duced blood flow to the foetus, causing foetal growth
restriction [5, 43–45, 47]. Increased maternal levels of
cortisol, as a cause and/or consequence of maternal de-
pression during pregnancy, might program the intra-
uterine developing HPA-axis of the child, making it
susceptible to increased stress reactivity in future life
[3, 4, 48], which has also been confirmed in animal
studies [49]. Therefore, where the earlier conducted
studies on antepartum depression and BLT only studied
the effects of BLT on mood [41, 42], it will be interesting
to examine the effects on infant stress reactivity, long-
term cortisol exposure and infant behaviour.
Aims
In this study, we will primarily study the effects of BLT on
depression during pregnancy, including adverse effects.
Second, we will study whether this clinical improvement
is accompanied by improved sleep quality and normalized
melatonin and cortisol levels during pregnancy. Third, we
will study the effects of BLT on gestational age, birth
weight, infant behaviour, infant cortisol stress response
and long-term cortisol exposure of the infant.
Methods/Design
Hypotheses
Primary hypothesis: Daily treatment with 6 weeks of
morning BLT improves depressive symptoms during
pregnancy.
Secondary hypotheses:
1. Clinical improvement of depressive symptoms is
accompanied by improved sleep patterns, lower
basal cortisol levels and normalized melatonin
concentrations during pregnancy.
2. Treatment with BLT during pregnancy improves
birth and child outcomes: higher gestational age,
higher birth weight, less regulation problems in
infants and lower cortisol stress response. In
addition, infants will show lower long-term
cortisol exposure.
Study overview
This study is a randomized, double-blind, placebo-
controlled clinical trial. After baseline measurements
(T0), the participants will be randomly allocated to ei-
ther receive active BLT or dim red light therapy (DRLT)
in a 1:1 ratio. Subsequently, they will commence their
daily treatment with light, which takes place at the par-
ticipants’ home for 6 weeks. After treatment, follow-up
will take place at the following time points:
 after 6 weeks of treatment, which marks the end of
treatment (T1);
 3 weeks after end of treatment (T2);
 10 weeks after end of treatment (T3);
 at birth (T4);
 2 months postpartum (T5);
 6 months postpartum (T6);
 18 months postpartum (T7).
At these time points, questionnaires, body material and
information from medical files will be collected (Table 1).
A flowchart of this study is shown in Fig. 3.
Participants
In this study, pregnant women with a depressive dis-
order will be eligible for participation. The specific
inclusion and exclusion criteria of the study are listed
in Table 2.
Recruitment
In the Netherlands, maternity care for low-risk preg-
nancies is provided in primary care, which is midwife-
led. High-risk pregnancies are cared for in a general
hospital (secondary care) or foetal-maternal medicine
unit (tertiary care).
In this study, women will be mainly recruited through
both midwifery practices and hospitals participating in
the South West Consortium in the Netherlands. This
is a unique consortium in which almost all parties
involved in perinatal care in the South West region of
the Netherlands are united: midwives, obstetricians,
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paediatrician, and several public health institutes. The
consortium covers both urban areas (such as the city
Rotterdam) and rural areas. Previous studies in this
consortium involved screening for psychosocial risk
factors, psychiatric disease and the impact of structur-
ing psychosocial care. Rotterdam is the second largest
city in the Netherlands with more than 620.000 inhabi-
tants [50]. It has a high number of deprived neighbour-
hoods, defined as 10 % of pregnant women having a
low socio-economic status (<20th percentile) [51].
Women will be routinely screened on psychopathology
and psychosocial problems during their first prenatal
visit in midwifery practices and hospitals by a screening
model, the Mind2Care [2]. During this screening,
women are asked to fill out a web-based questionnaire,
consisting of 33 items, covering four domains: a socio-
demographic, obstetric, psychiatric and psychosocial
domain, including the Edinburgh Postnatal Depression
Scale (EPDS) [52]. A cut-off score of 9 or above of the
EPDS is used by the Mind2Care, in order to refer a
woman towards tailored mental health care. Sensitivity
and specificity of the EPDS are respectively 86 and
78 % [52].
In addition, women who visit our outpatient psychi-
atric clinic – a centre of excellence in perinatal psych-
iatry – at the Erasmus University Medical Centre in
Rotterdam for their depressive symptoms will be of-
fered to participate in our study when they are not fully
remitted from depressive symptoms after 2 months of
treatment with antidepressant medication and/or other
psychiatric treatment.
Third, pregnant women who visit their general prac-
titioner (GP) for depressive symptoms may be referred
to the study by their GP.
Finally, women will be recruited via (social) media, such
as press releases, so women with depressive symptoms
can enrol in the study without referral from their midwife,
gynaecologist, GP or mental health care worker.
Ethics
This study will be conducted in accordance with the
Helsinki Declaration, meaning that participation is vol-
untary and written informed consent will be obtained.
Before entering the study, subjects will receive informa-
tion about the study and its risks and benefits, verbal
and in writing. Subjects will have a reflection period of
one week. Participants can leave the study at any time
for any reason without consequences with regard to
their current or future treatment. Also, the investigator
can decide to withdraw a participant from the study for
urgent medical reasons.
The study has been approved by the medical ethical
committee of the Erasmus University Medical Centre,
Rotterdam, The Netherlands (registration number MEC-
2015-731). A Data Safety Monitoring Board has been
installed, which monitors the safety of this research.
In case of adverse effects, a treatment protocol will be
effective.
Randomization and blinding
We will randomly assign 150 participants in a 1:1 alloca-
tion ratio to either receive BLT or DRLT. Randomization
will be done with the web-based computer-generated
randomization schedule ALEA (software for randomization
in clinical trials, version 2.2) using random block sizes of
2 to 6. Stratification factors will be the use of any anti-
depressant medication and the number of previous
depressive episodes. This will be dichotomized to 3 or
less previous depressive episodes versus 4 or more [53].
Participants will be blinded for their allocation. They
will be informed that this study examines the efficacy of
light therapy with two different colours.
Participants will be asked to guess to which treatment
group they are allocated to after treatment, as suggested
by the Cochrane’s Collaboration’s tool for assessing risk
of bias in randomized trials [54].
Table 1 Overview assessment of questionnaires and collection
of body material and medical files per time point
T0 IP a T1 T2 T3 T4 T5 T6 T7
Questionnaires
SIGH-SAD X X X X X X X X
EPDS X X X X X X X X
Life events X X X X X X X X
PSQI X X X X X X
User expectations X
User experiences X X
MABS X
CBCL X
Body material
Urine cortisol X X X X
Saliva cortisol/melatonin X X X X
Hair cortisol X X X
Saliva cortisol (infant) X
Hair cortisol (infant) X
Actigraphy X b X c X c
Collecting medical files X
T0 baseline (start of treatment), T1 after 6 weeks of treatment (end of treatment),
T2 = 3weeks after treatment, T3 = 10weeks after treatment, T4 birth, T5 2 months
postpartum, IP intervention period, SIGH-SAD Structured Interview Guide for the
Hamilton Depression Scale – Seasonal Affective Disorder version, EPDS Edinburgh
Postnatal Depression Scale, PSQI Pittsburgh Sleep Quality Index, MABS Mother
and Baby Scales, CBCL Child Behaviour Checklist
aIn the intervention period, the questionnaires will be assessed weekly
bThe actiwatch needs to be worn for 8 weeks at T0
cAt T3 and T5, the actiwatch needs to be worn for 9 days
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Blinded, independent assessors will be involved in the
outcome ratings and will conduct the interviews at T1,
T2, T3, T5, T6 and T7 and on a weekly base during the
intervention period. The participants are asked not to
share any details about their treatment towards the as-
sessors. In case information is shared, the assessor will
be replaced. After each interview, the assessors will be
asked to guess the allocation of the participant.
The researcher who will perform the primary statistical
analysis (AK) will be blinded for allocation.
The field researcher (BB) will install the lamps and will
provide the participants with instructions. Also, the field
researcher will answer any questions asked by participants.
For this, we will use protocolled answers, to maintain the
blindness of the participants. Moreover, the field re-
searcher will ask the participants about side-effects at T1
and on a weekly base during the intervention, keeping the
independent assessors blinded for adverse effects that
might break the blinding, e.g. strained eyes. For these
practical reasons, the field researcher will not be blinded.
Intervention
Participants will be randomly allocated to BLT (9.000
lux) or DRLT (100 lux). Treatment will take place daily
at home for 6 weeks, starting at 12–18 weeks pregnancy.
Participants will be asked to commence the treatment
Fig. 3 Flowchart of overview study. DSM = Diagnostic and Statistical Manual of Mental Disorders; BLT = bright light therapy; DRLT = dim red
light therapy
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within 30 min of habitual wake-up time with a duration
of 30 min. Participants will sit in front of two light boxes
with a distance of approximately 40 cm. The light boxes
will be placed in a custom-made scaffolding. In this way,
the height of the light boxes can be adjusted per person,
ensuring the same distance. Also, the scaffolding ensures
lighting from above, which avoids glare [42]. This makes
the treatment more comfortable, enhancing treatment
adherence.
The active dose was found effective in other studies
[23, 41, 42]. Dim red light can be considered to be bio-
logically inactive [55]. Although a Cochrane review of
studies in BLT in non-seasonal depression showed that
BLT may be effective in as little as 1 week [55], we will
choose 6 weeks of daily light exposure, since the 2
studies among pregnant women with non-seasonal de-
pression showed significant effects of BLT from 5 weeks
treatment [41, 42].
All participants in both treatment arms will receive
treatment as usual. Women are always free to visit their
GP, whenever they are in need of this. The GP is always
free to start treatment if he/she feels necessary.
When depressive symptoms increase and/or in the
case of suicidal ideation, an action plan is set up and
appropriate measures will be taken.
Different measures have been taken to enhance treat-
ment adherence:
 A sensor that measures the amount of lux perceived
is installed in the actiwatches, which will monitor
the therapy adherence.
 Since the lamps will be installed into a custom-
made scaffolding that ensures lighting from above,
treatment will be more comfortable, which enhances
treatment adherence.
Outcome measures
The primary outcome measure will be the average
change in depressive symptoms between the two groups,
as measured by the Structured Interview Guide for the
Hamilton Depression Scale – Seasonal Affective Dis-
order version (SIGH-SAD) and the EPDS at different
time points. Second, we will study responders vs. non-
responders, where response is defined as a ≥50 % decrease
to a final score of ≤ 8 on the 17-item Hamilton scale
and ≤ 5 on the EPDS.
The secondary outcome measures of this study will be
the changes in maternal cortisol and melatonin levels
(1), in maternal circadian rhythm (2) and in birth and
child outcomes (3).
1. Morning and evening cortisol levels in saliva will be
measured as a measure for HPA-axis activity. Morning
and evening melatonin levels in saliva will be measured
as measure of a participant’s circadian phase position.
Outcome measures will be the changes in cortisol and
melatonin saliva levels between the two groups.
Total 24-h cortisol excretion will be determined from
urine. Outcome measure will be the changes in
cortisol levels within and between the two groups.
2. Hair will be used as a long-term measure for cortisol
excretion. Changes in levels between the two groups
will be used as outcome measure.
3. Through actiwatches and a structured questionnaire
(the Pittsburgh Sleep Quality Index – PSQI),
information will be obtained regarding total sleep
time, sleep efficiency and sleep onset latency, as
well as circadian estimates from the rest activity
rhythm such as intradaily and interdaily variability
and rhythm amplitude.
4. Differences in birth and child outcomes between
the two groups will be used as outcome measures:
pregnancy duration, birth weight, child behaviour,
long-term cortisol exposure and cortisol stress
response at a routine vaccination.
Finally, we will ask about user expectations and user
experiences.
Complete follow-up will be pursued. In case of discon-
tinuing or deviating from the intervention, we will collect
outcomes of EPDS and SIGH-SAD assessment.
Sample size
Based on previous literature [23, 41, 56], we expect a
small to moderate response (time x treatment interaction
Table 2 Inclusion and exclusion criteria
Inclusion criteria Women
18–45 years of age
12–18 weeks pregnant
DSM-V diagnosis of depressive disorder (as assessed
by the Structured Clinical Interview for DSM disorders)
Exclusion criteria Insufficient proficiency in Dutch or English
Multiple pregnancy
The use of antidepressants shorter than 2 months
Bipolar I or II disorder
Any psychotic episode
Substance abuse
Primary anxiety disorder
Recent history of suicide attempt
Shift-work
Somatic and/or obstetric conditions that override
study participation
Previous treatment with BLT
Eye condition (macular degeneration, eye diseases,
recent eye surgery)
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on depressive symptoms). This corresponds to a 10 to
15 % reduction of depressive symptoms over the full
course of treatment. To demonstrate this (with an α of
0.05 and a β of 0.80), we will need a sample size of 63
participants per arm (126 in total). To account for lost
to follow up during and after treatment, we will aim at
including 150 participants. Power calculations were per-
formed using GLIMMPSE 2.1.5 software [57].
In case of withdrawal of a participant during the re-
cruitment period, another participant will be recruited
to obtain the aimed number of participants.
Adverse effects
At every measurement, we will ask for adverse effects.
The adverse effects of BLT, such as headache and nau-
sea, are generally mild and short-lived [58, 59]. A switch
to hypomania is a more serious adverse effect, which
would require effect managing. In a study exploring the
side effects of short-term 10,000 lux light therapy in 70
patients suffering from SAD, 1 subject experienced
hypomania [58]. In the two studies (n = 10 and n = 27)
studying the effects of light therapy in a pregnant popu-
lation, 1 subject showed hypomanic symptoms [41, 42].
If a participant shows hypomanic symptoms, the daily
treatment duration will be reduced. This enhances the
clinical safety [41].
No adverse effects for the foetus will be expected [42, 56].
Inclusion
Women will be asked to provide the following baseline
socio-demographic factors: age, ethnicity, level of edu-
cation, marital status, parity, unplanned pregnancy,
body mass index, somatic conditions (if not exclusion),
medication use and substance use (smoking, alcohol,
drugs).
The GP will be contacted to verify whether the par-
ticipant meets any exclusion criteria. The results will
be discussed with an experienced perinatal psych-
iatrist (ML), who will – as a safety measure – verify
the diagnosis and inclusion and exclusion criteria. If
there are no clinical contraindications, randomization
will take place.
After a positive screening on the EPDS, eligible
women will be interviewed to assess lifetime psychi-
atric diagnosis. This will be done with the Structured
Clinical Interview for DSM disorders (SCID), a semi-
structured interview that is considered to be the golden
standard for making the major DSM-V axis I psychi-
atric diagnoses [60].
Measurements
Primary outcome measures
Depressive symptoms during pregnancy will be assessed
using the SIGH-SAD and the EPDS.
SIGH-SAD
The SIGH-SAD is a 29-item structured interview and
consists of 21 HAM-D (Hamilton Rating Scale for De-
pression) items and 8 atypical items, of which 11 items
can be scored with a value of 0–2, 5 items with a value
of 0–3 and 13 items with a value of 0–4 [61]. The sum
score ranges from 0 to 63 for the HAM-D items and
from 0 to 26 for the atypical items, resulting in a total
sum score of 0 to 89 [61].
We will choose the original 17-item HAM-D question-
naire as primary measure, since it is more commonly
used in clinical practice and research. Interrater reliabil-
ity for the 17-item HAM-D questionnaire ranges from
0.82 to 0.98 [62]. Sensitivity and specificity are respect-
ively 0.76 and 0.91 [62]. Positive and negative predictive
value are respectively 0.77 and 0.92 [62]. Next to the
original 17-item HAM-D questionnaire, we will use the
entire SIGH-SAD questionnaire, since this question-
naire is the current benchmark for assessment of severity
of depression in light therapy trials.
EPDS
The EPDS, a structured 10-item questionnaire, will be
used as a validated self-report measure of depression
during pregnancy [52, 63]. Each item is scored with a
value, ranging from 0 to 3, which leads to a sum score
of 0 to 30 [52]. Sensitivity and specificity of the EPDS
are respectively 86 and 78 % [52]. Originally, the EPDS
was developed for the detection of postnatal depression,
but has been validated for screening depression during
pregnancy as well [63]. In this study, we will use a cut-
off of 9, in accordance with the screening tool, the
Mind2Care [2].
Secondary outcomes (endocrine)
Endocrine levels during pregnancy will be studied
measuring saliva melatonin and cortisol in urine, saliva
and hair.
Urinary free cortisol
Urinary free cortisol levels during a 24-h period provide
a non-invasive valid estimation of overall daily cortisol
production [64]. Urine will be collected starting after the
first voided urine after awakening and will include the
first voided urine on the following day. The cortisol level
will be determined by radioimmunoassay. Completeness
of collection will be ascertained by interviews document-
ing urine losses. Only complete collections, with creatinine
within the normal range of 0.06 mg/dL per 24 h will be
included in the analysis.
Saliva cortisol
As a measure of HPA-axis activity, saliva cortisol will be
collected using cotton dental rolls, including 4 sequential
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samples at 30-min intervals starting at awakening and 3
sequential samples at hourly intervals starting 2 h before
predicted bedtime with the last sample at bedtime. The
samples will be collected the following day and subse-
quently delivered to the laboratory, where they will be
centrifuged and stored at −80 °C. Samples will be ana-
lysed using a cortisol assay on an immunoanalyser sys-
tem. For determination of the diurnal time course of
saliva cortisol levels, only days with at least 6 valid
samples will be included in analyses.
Hair cortisol
Hair cortisol will be assessed as a validated biomarker
for long-term cortisol exposure. The maternal hair strands
will be collected and processed according to existing
methods [65]. With this method, cortisol levels can be
retrospectively assessed depending on hair length (i.e. one
month for each centimetre of hair). Norm data from
healthy pregnant controls will be available through one of
our other ongoing studies.
Saliva melatonin
As a measure of a participant’s circadian phase position,
saliva melatonin levels will be collected using cotton
dental rolls at hourly intervals with 3 sequential samples,
starting 2 h before predicted bedtime with the last sam-
ple at bedtime, under dim light conditions. One sample
will be taken at awakening. The samples will be collected
the following day and subsequently delivered to the labora-
tory, where they will be centrifuged and stored at −80 °C.
All samples will be analysed using Liquid Chromatography
Tandem Mass Spectrometry (LC-MS/MS). For deter-
mination of a rise in melatonin levels in het evening,
only days with 3 valid evening samples will be included
in the analyses [23].
The Dim Light Melatonin Onset (DLMO; the time
point when melatonin secretion rises over a predefined
threshold in the evening [66]) will be calculated after
measuring the melatonin evening curve. The DLMO is a
reliable estimate of circadian phase position [66].
Secondary outcome measures (circadian rhythm)
The circadian rhythm during pregnancy will be studied
through actiwatches and the PSQI.
Actigraphy
Actigraphy, the continuous assessment of activity with a
watch-sized non-dominant wrist-worn recorder (Actiwatch
Spectrum, Philips Respironics, Pittsburgh, USA), is a
validated technique to obtain estimates of sleep and
rest-activity rhythms [23, 67, 68]. Sleep analyses software
(Actiware 6.0, Philips Respironics, Pittsburgh, USA) will
be used to obtain estimates of sleep parameters. The
software will calculate end and start of sleep. Further,
assumed sleep (the difference between the end and the
start of sleep), actual sleep time (amount of sleep deter-
mined by algorithm), sleep onset latency (the time be-
tween lights out and sleep onset) and sleep efficiency
(the percentage of actual sleep time between sleep on-
set and final awakening, excluding sleep onset latency)
will be calculated [23]. Rest-activity rhythms will be
calculated, using different actimetric variables, such as
interdaily stability and intradaily variability [23].
PSQI
The PSQI, a structured 19-item self-questionnaire with
5 additional items reported by bedpartner, assesses sleep
quality, including a wide variety of factors, such as sleep
duration and latency [69]. The sum score ranges from 0
to 21 points, with higher values corresponding to lower
sleep quality [69]. These 19 items generate 7 component
scores: subjective sleep quality, sleep latency, sleep dur-
ation, habitual sleep efficiency, sleep disturbances, use
of sleeping medication and daytime dysfunction [69].
A cut-off of 5 will be applied, where a score of <5 in-
dicates poor sleep and ≥5 indicates good sleep [69].
The PSQI has a sensitivity of 89.6 % and a specificity of
86.5 % [69].
The PSQI will be assessed on a monthly base and
weekly in the intervention period.
Secondary outcome measures (infant)
As infant outcome measures, birth outcomes, infant
stress response, infant long-term cortisol exposure and
behaviour will be studied.
Birth outcomes
After birth (T4), information will be obtained regarding
complications during delivery and childbirth from the
medical records: hypertension, pre-eclampsia, delivery
aspects (duration, start with or without induction, aug-
mentation, method of pain relief if any, instrumental
delivery, caesarean section, hospital admission) and first
week complications after delivery.
Infant stress response
To measure the infant stress response, we will collect
saliva cortisol before and 15, 30 and 45 min after a rou-
tine vaccination at T5. We will use the same procedures
and analyses as with the mothers.
Infant long-term cortisol exposure
To measure the long-term cortisol (intra-uterine) ex-
posure, we will collect hair samples of the infant at T5.
We will use the same procedures and analyses as with
the mothers.
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Infant behaviour
To study infant behaviour, we will assess the ques-
tionnaires Mother and Baby Scales (MABS) and Child
Behaviour Checklist (CBCL).
MABS
We ask mothers (and fathers, if available) to fill out the
MABS, a questionnaire consisting of various subscales
[70]. In this study, we use 3 subscales of the MABS: infant
alertness-responsiveness, unsettled-irregular behaviour
of the infant and lack of confidence in care-taking [70],
resulting in a 36-item questionnaire.
The unsettled-irregular behaviour scale consists of 8
items (e.g. ‘After feeds, I’ve used rocking or cuddling to
settle my baby), the alertness-responsiveness scale of 15
items (e.g. ‘My baby watches my face’) and the lack of
confidence in feeding of 13 items (e.g. ‘I’ve felt clumsy in
caring for my baby’). Parents are asked to score the vari-
ous statements with a score between 0 (not at all) and 5
(very much/often), which results in a sum score of 0–180.
The subscale sum scores range from 0 to 75 for infant
unsettled-irregular behaviour, from 0 to 40 for infant
alertness-responsiveness and from 0 to 65 for lack of con-
fidence in care-taking [70]. A higher score on the infant
unsettled-irregular behaviour scale correlates to more
irregular behaviour, whereas a higher score on the infant
alertness-responsiveness scale points to more alert behav-
iour [71]. A higher score on the lack of confidence scale
suggests that the mother is less confident in taking care of
the baby. Reliability of the MABS ranges from 0.81 to 0.93
(Cronbach’s α), depending on the used subscale [70].
CBCL
We ask mothers (and fathers, if available) to fill out the
CBCL/1.5–5, a diagnostic 99-item questionnaire which
quantifies skills and behavioural problems. The question-
naire consists of different scales: emotionally reactive,
anxious/depressed, somatic complaints, withdrawn, sleep
problems (Internalizing Problems), attention problems
and aggressive behaviour (Externalizing Problems) [72].
Together, the Externalizing and Internalizing Problems
form the Total Problems [72]. Items can be scored with 0
(not at all), 1 (a little or sometimes) or 2 (clearly or often),
resulting in different sum scores for the different scales.
Norms for these scales were constructed, using a large
representative sample of children [72].
Reliability of the CBCL is 0.85 [73].
Chronotype
The participant’s chronotype will be verified at screening,
since evening types are found to be more prone to depres-
sion than morning types [74, 75]. In this study, this will be
assessed with the Munich Chronotype Questionnaire
(MCTQ), a structured 19-item self-report measure of
an individual’s chronotype, based on sleep times, self-
reported light exposure and self-assessed chronotype (ex-
treme, moderate or slight early, normal or slight, moderate
or extreme late), taking rest and working days in consider-
ation [76]. The participant can be classified to 1 of the 7
chronotypes by utilizing data on the participant’s midsleep
phase and sleep debt [76]. Sum score ranges from 16 to
86, with the lowest score indicating extreme late chrono-
types. The MCTQ correlates well with the Horne-Östberg
Morningness-Eveningness Questionnaire – especially the
MCTQ-assessment of time of midsleep (r = −0.73 on free
days and r = −0.61 on workdays) [77].
Statistical analysis
General
Data will be analysed using SPSS 21.0. For treatment ef-
fect analyses, we will apply an intention-to-treat proced-
ure, since none of the participants will switch to another
condition and we will include all observations of all par-
ticipants until study end or withdrawal.
If necessary, skewed continuous variables will be trans-
formed to normality prior to the analyses.
For the continuous variables and categorical variables
that are assessed more than twice, we will deploy linear
mixed models and generalized linear mixed models re-
spectively. These models use all available data and ac-
count for within-subject correlation over time. They can
also be used to adequately deal with possible baseline
imbalances. Variables measured only once will be com-
pared between the randomized groups using the un-
paired t-test, or the Chi-Square test in case of
categorical variables. All effect parameters will be sup-
plied with a 95 % confidence interval.
Primary outcome analysis will be first crude, than ad-
justed. If despite randomization, prognostically import-
ant factors differ between the groups, they will be
adjusted for supplemental analyses.
Primary outcomes
Changes in HAM-D and EPDS rating scale scores over
time will be analysed using generalized linear mixed
models. Differences from baseline of HAM-D and EPDS
scores at every time point will be the dependent variables,
time will be the within-subject factor and treatment (BLT
versus DRLT) will be the between-subjects factor.
Additional analysis will use alternative definitions of
change: instead of the numerical difference of scores
before and after, we will use a dichotomous response
variable where improvement of ≥ 50 % to a final score ≤
8 on HAM-D and ≤ 5 on EPDS is defined as success,
otherwise not. Finally, we will perform sensitivity ana-
lysis to examine robustness of the findings with other
methods using data imputation (last observation carried
forward multiple imputation).
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Secondary outcomes
For saliva cortisol, areas under the curves for the morning
and evening (i.e. 7 to 9 AM and 8 to 11 PM) will be calcu-
lated for subsequent analyses [23]. For saliva melatonin,
areas under the curves for the evening (i.e. 8 to 11 PM)
will be calculated for subsequent analyses [23].
Continuous outcomes, e.g. saliva cortisol and mela-
tonin, will be tested with the unpaired t-test and linear
mixed model. Categorical outcomes, e.g. sleep quality,
will be tested with Chi-Square Test and generalized
linear mixed model.
Covariates
Potential covariates for the mother are psychiatric his-
tory, ethnicity, level of education, parity, gestational age
(duration of pregnancy at study entry), substance use,
chronotypes, duration of actual depression and other
psychiatric or psychotherapeutic treatment interventions.
These factors might affect depressive symptoms during
pregnancy. After pregnancy, we will additionally correct
for complications during delivery, breastfeeding and ob-
jective and subjective sleep parameters, since these factors
might influence depressive symptoms after delivery.
Potential covariates for the infant are head circumfer-
ence, congenital malformations, Apgar-score and neonatal
admission at Neonatal Intensive Care Unit.
Discussion
We have presented a protocol for an RCT of light therapy
for antepartum depression. Two earlier conducted RCT’s
have shown the effects of BLT in pregnant women with
depression, but studied only a small sample size (n = 10
and n = 27) [41, 42]. In this trial, we will study the effects
of BLT on antepartum depression in a larger sample
(n = 150) and in addition to the earlier conducted studies,
we will not only study the effects of BLT on the mother,
but on the infant as well. Moreover, we will study the
effects of BLT on maternal endocrine levels and maternal
circadian rhythm.
BLT will benefit pregnant women, for they will receive
immediate treatment for their depressive symptoms.
Psychotherapists are not always available, which would
postpone treatment. Also, antidepressant medication is
not immediately effective. However, BLT may be effective
in as little as 1 week [55]. Moreover, the adverse effects of
BLT are mild and short-lived.
The unborn child would benefit from this alternative
treatment, for BLT does not cause adverse effects in the
unborn child. Also, since BLT may be effective in a short
time period, the risks associated with maternal depres-
sion (such as lower birth weight) may be diminished.
BLT would benefit society, since BLT has lower
costs than treatment with antidepressant medication
or psychotherapy.
Finally, since this RCT would be the first to study the
effects of BLT in the infant, it would contribute to the
understanding of the role of BLT, depression and the
maternal HPA-axis in the developing foetus.
Thus, if BLT reduces depressive symptoms in pregnant
women, it will provide an alternative, non-pharmalogical
treatment for psychotherapy and antidepressant medica-
tion in treating antepartum depression. BLT combines
direct availability, sufficient efficacy, low costs and high
safety, taking the safety for the unborn child into account
as well. Moreover, it does not require good language skills
and it can be administered at home. These considerations
make BLT for treating depression in pregnant women
relevant, especially in urban multi-ethnic populations
with high prevalence of depression and a low level of
personal resources.
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